|
Market Closed -
Nasdaq
15:51:24 2026-08-14 EDT
|
5-day change | 1st Jan Change | ||
| 1.950 USD | -2.01% |
|
-2.01% | -39.63% |
Company Valuation: Alaunos Therapeutics, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Market Cap 1 | 536.6 | 234 | 155.4 | 16.98 | 3.05 | 7.209 |
| Change | - | -56.4% | -33.56% | -89.08% | -82.04% | 136.32% |
| Enterprise Value (EV) 1 | 426.3 | 187.3 | 135.9 | 10.92 | 1.959 | 5.824 |
| Change | - | -56.08% | -27.43% | -91.96% | -82.06% | 197.23% |
| P/E | -6.61x | -2.97x | -3.74x | -0.48x | -0.65x | -1.47x |
| PBR | 4.35x | 4.04x | 4.03x | 2.69x | 1.48x | 3.52x |
| PEG | - | 0.8x | 0.1x | 0x | 0x | 0.1x |
| Capitalization / Revenue | - | 587,819,588x | 53,196,617x | 3,396,281,000x | 305,038,500x | 1,441,761,400x |
| EV / Revenue | - | - | - | - | - | - |
| EV / EBITDA | -5.38x | -2.52x | -4.53x | -0.42x | -0.41x | -1.38x |
| EV / EBIT | -5.31x | -2.44x | -4.15x | -0.38x | -0.41x | -1.38x |
| EV / FCF | -11.8x | -5.36x | -4.86x | -2.14x | -0.59x | -7.73x |
| FCF Yield | -8.45% | -18.7% | -20.6% | -46.7% | -168% | -12.9% |
| Dividend per Share 2 | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - |
| EPS 2 | -57.22 | -55.1 | -26.06 | -22 | -2.922 | -2.198 |
| Distribution rate | - | - | - | - | - | - |
| Net sales | - | 0.398 | 2.922 | 0.005 | 0.01 | 0.005 |
| EBITDA 1 | -79.23 | -74.21 | -29.98 | -26.18 | -4.81 | -4.218 |
| EBIT 1 | -80.36 | -76.81 | -32.74 | -28.49 | -4.812 | -4.225 |
| Net income 1 | -79.98 | -78.75 | -37.73 | -35.14 | -4.679 | -4.176 |
| Net Debt 1 | -110.3 | -46.69 | -19.55 | -6.062 | -1.091 | -1.385 |
| Reference price 2 | 378.000 | 163.500 | 97.365 | 10.605 | 1.905 | 3.230 |
| Nbr of stocks (in thousands) | 1,420 | 1,431 | 1,596 | 1,601 | 1,601 | 2,232 |
| Announcement Date | 3/1/21 | 3/30/22 | 3/7/23 | 4/1/24 | 3/31/25 | 3/31/26 |
1USD in Million2USD
Estimates
| P/E (N) | EV / Sales (N) | EV / EBITDA (N) | Dividend Yield (N) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | - | - | - | - | 4.82M | |
| 21.38x | 7.5x | 15.3x | 1.35% | 71.56B | |
| 31.01x | 7.89x | 24.08x | 0.05% | 54.43B | |
| -79.85x | 14.92x | -76.15x | -.--% | 27.59B | |
| 30.34x | 5.94x | 15.73x | -.--% | 23.91B | |
| -14.5x | 5.07x | -6.61x | -.--% | 23.14B | |
| 25.57x | 4.84x | 16.25x | -.--% | 18.65B | |
| 58.2x | 20.62x | 42.08x | 0.07% | 18.64B | |
| -1217.84x | 38.05x | -15079.66x | -.--% | 16.01B | |
| 15.7x | 4.62x | 10.79x | -.--% | 12.54B | |
| Average | -125.56x | 12.16x | -1,670.91x | 0.16% | 26.65B | |
| Weighted average by Cap. | -61.29x | 10.43x | -899.29x | 0.38% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- TCRT Stock
- Valuation Alaunos Therapeutics, Inc.
Select your edition
All financial news and data tailored to specific country editions
